104 related articles for article (PubMed ID: 24649766)
1. [Results of treatment of patients with prostatic adenoma using silodosin based on an assessment of the phenotype of male sexuality].
Kogan MI; Kireev AIu
Urologiia; 2013; (6):58-60. PubMed ID: 24649766
[TBL] [Abstract][Full Text] [Related]
2. [SILODOSIN IN THE TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA--RESULTS OF RUSSIAN MULTICENTER OBSERVATIONAL STUDY].
Pushkar DY; Bernikov AN; Sadchenko AV
Urologiia; 2015; (5):31-4, 36-7. PubMed ID: 26859934
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of prostatic adenoma treatment with alfusozine depending on sexuality].
Kogan MI; Kireev AIu
Urologiia; 2011; (1):28-31. PubMed ID: 21500491
[TBL] [Abstract][Full Text] [Related]
4. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
5. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
Schilit S; Benzeroual KE
Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
[TBL] [Abstract][Full Text] [Related]
6. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
[TBL] [Abstract][Full Text] [Related]
7. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
8. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
J Urol; 2009 Jun; 181(6):2634-40. PubMed ID: 19371887
[TBL] [Abstract][Full Text] [Related]
9. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
Homma Y; Kawabe K; Takeda M; Yoshida M
Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263
[TBL] [Abstract][Full Text] [Related]
10. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
11. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
J Urol; 2013 Jan; 189(1 Suppl):S122-8. PubMed ID: 23234617
[TBL] [Abstract][Full Text] [Related]
12. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
[TBL] [Abstract][Full Text] [Related]
13. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Watanabe T; Ozono S; Kageyama S
J Int Med Res; 2011; 39(1):129-42. PubMed ID: 21672315
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
[TBL] [Abstract][Full Text] [Related]
15. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
Capitanio U; Salonia A; Briganti A; Montorsi F
Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
[TBL] [Abstract][Full Text] [Related]
16. [Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia].
Neĭmark AI; Nozdrachev NA
Urologiia; 2013; (4):47-8, 50-1. PubMed ID: 24159765
[TBL] [Abstract][Full Text] [Related]
17. [Optimum initial dose of silodosin for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia].
Wada N; Numata A; Yamaguchi S; Osanai H; Mori T; Hou K; Fujisawa M; Kaneko S; Kakizaki H
Hinyokika Kiyo; 2011 Jun; 57(6):297-302. PubMed ID: 21795831
[TBL] [Abstract][Full Text] [Related]
18. [Experience of the use of drug urorec: efficacy and safety].
Kadiev RM; Derevianko TI
Urologiia; 2014; (3):44, 46-7. PubMed ID: 25211926
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
[TBL] [Abstract][Full Text] [Related]
20. Silodosin for benign prostatic hyperplasia.
Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
